These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 19680296)

  • 21. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy for advanced stage non-small cell lung cancer.
    Fathi AT; Brahmer JR
    Semin Thorac Cardiovasc Surg; 2008; 20(3):210-6. PubMed ID: 19038730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy for non-small cell lung cancer.
    Toloza EM; D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for lung cancer: the state of the art in 2009.
    Higgins MJ; Ettinger DS
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1365-78. PubMed ID: 19827996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel targeted therapies for non-small cell lung cancer.
    Smith PW; Denlinger CE; Jones DR
    Thorac Surg Clin; 2006 Nov; 16(4):353-66. PubMed ID: 17240823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of unfit older patients with advanced NSCLC.
    Gridelli C; Maione P; Rossi A; Palazzolo G; Colantuoni G; Rossi E
    Cancer Treat Rev; 2009 Oct; 35(6):517-21. PubMed ID: 19457617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies and non-small-cell lung cancer: work in progress?
    Gridelli C
    Curr Opin Oncol; 2006 Mar; 18(2):132-4. PubMed ID: 16462181
    [No Abstract]   [Full Text] [Related]  

  • 31. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Stage IV non-small cell lung cancer. What is the best treatment for relapse?].
    Sculier JP
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S78-16S83. PubMed ID: 17268341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-small cell lung cancer - from treatment of relapse to treatments for relapses].
    Souquet PJ
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S108-13. PubMed ID: 18235402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biological therapy in non-small-cell lung cancer (NSCLC)].
    Souquet PJ
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S53-4S56. PubMed ID: 15687996
    [No Abstract]   [Full Text] [Related]  

  • 36. New advances in the second-line treatment of small cell lung cancer.
    Hurwitz JL; McCoy F; Scullin P; Fennell DA
    Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
    Engelman JA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4637-40. PubMed ID: 17671156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs].
    Cadranel J
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S10-1. PubMed ID: 17242637
    [No Abstract]   [Full Text] [Related]  

  • 40. Small cell lung cancer and targeted therapies.
    Blackhall FH; Shepherd FA
    Curr Opin Oncol; 2007 Mar; 19(2):103-8. PubMed ID: 17272981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.